Hosted on MSN1mon
Roche's Susvimo gets FDA approval for diabetic macular edema
Roche's (OTCQX:RHHBY) Genentech unit has received FDA approval for its drug Susvimo 100 mg/mL injection for the treatment of diabetic macular edema, a leading cause of blindness for people with ...
pharmaphorum4d
FDA clears Roche's Susvimo implant for eye disease wet AMD
Roche's Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration (AMD) that gives patients an alternative to regular injections ...
pharmaphorum1mon
FDA expands label for Roche's eye disease implant Susvimo
The renaissance of Roche's refillable ophthalmic implant Susvimo has continued with FDA approval for use in patients with diabetic macular oedema (DME), a leading cause of vision loss and blindness.
MarketWatch1mon
Roche: FDA Approves Susvimo for Treatment of Diabetic Macular Edema
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...